Vaccination of melanoma patients with Melan-A/Mart-1 peptide and Klebsiella outer membrane protein p40 as an adjuvant

Lienard, Danielle; Avril, Marie-Françoise; Le Gal, Frédérique-Anne; Baumgaertner, Petra; Vermeulen, Wim; Blom, Astrid; Geldhof, Christine; Rimoldi, Donata; Pagliusi, Sonia; Romero, Pedro; Dietrich, Pierre-Yves; Corvaia, Nathalie; Speiser, Daniel Ernest

doi:10.1097/CJI.0b013e3181b56ad9

Advanced search

Browse by...

Deposit

Highlights

More informations

Title		Vaccination of melanoma patients with Melan-A/Mart-1 peptide and Klebsiella outer membrane protein p40 as an adjuvant
Authors		Lienard, Danielle Avril, Marie-Françoise Le Gal, Frédérique-Anne Baumgaertner, Petra Vermeulen, Wim Blom, Astrid Geldhof, Christine Rimoldi, Donata Pagliusi, Sonia Romero, Pedro Dietrich, Pierre-Yves Corvaia, Nathalie Speiser, Daniel Ernest show all authors [1 - 13]
Published in		Journal of Immunotherapy. 2009, vol. 32, no. 8, p. 875-883
Abstract		Toll-like receptor ligands are potentially useful adjuvants for the development of clinical T cell vaccination. Here we investigated the novel Toll-like receptor2 ligand P40, the outer membrane protein A derived from Klebsiella pneumoniae. Seventeen human leukocyte antigen-A*0201 positive stage III/IV melanoma patients were vaccinated with P40 and Melan-A/Mart-1 peptide subcutaneously in monthly intervals. Adverse reactions were mild-to-moderate. Fourteen patients received at least 8 vaccinations and were thus evaluable for clinical tumor and immune responses. Seven patients experienced progressive disease, whereas 2 patients had stable disease throughout the trial period, 1 of them with regression of multiple skin metastases. The remaining 5 patients had no measurable disease. Melan-A/Mart-1 specific CD8 T cells were analyzed ex vivo, with positive results in 6 of 14 evaluable patients. Increased percentages of T cells were found in three patients, memory/effector T cell differentiation in 4 patients, and a positive interferon-gamma Elispot assay in 1 patient. Antibody responses to P40 were observed in all patients. We conclude that vaccination with peptide and P40 was feasible and induced ex vivo detectable tumor antigen specific T cell responses in 6 of 14 patients with advanced melanoma.
Keywords		Adjuvants, Immunologic/administration & dosage — Adult — Aged — Aged, 80 and over — Antigens, Neoplasm/administration & dosage — Bacterial Outer Membrane Proteins/administration & dosage — CD8-Positive T-Lymphocytes/metabolism/pathology — Cancer Vaccines — Female — HLA-A Antigens/metabolism — HLA-A2 Antigen — Humans — Klebsiella pneumoniae/immunology — MART-1 Antigen — Male — Melanoma/immunology/pathology/physiopathology/therapy — Middle Aged — Neoplasm Proteins/administration & dosage — Neoplasm Staging — Peptide Fragments/administration & dosage — Skin Neoplasms/immunology/pathology/physiopathology/therapy
Identifiers		DOI: 10.1097/CJI.0b013e3181b56ad9 PMID: 19752746
Full text		Article - Limited access to UNIGE
Structures		Faculté de médecine / Section de médecine clinique / Département de médecine Faculté de médecine / Section de médecine clinique / Département des neurosciences cliniques
Research group		Immunothérapie des cancers (42)
Citation (ISO format)		LIENARD, Danielle et al. Vaccination of melanoma patients with Melan-A/Mart-1 peptide and Klebsiella outer membrane protein p40 as an adjuvant. In: Journal of Immunotherapy, 2009, vol. 32, n° 8, p. 875-883. https://archive-ouverte.unige.ch/unige:19925